On August 26, 2024, Regeneron filed a BPCIA complaint in the District Court for the District of New Jersey against Sandoz Inc. related to Sandoz’s ENVEEZU (aflibercept-abzv).  This is the fifth BPCIA litigation regarding aflibercept, following Regeneron’s litigations against Biocon/Mylan, Samsung Bioepis, and Formycon, and Amgen, which have been consolidated for pretrial proceedings in a…